3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Gynecologic
1
Gastrointestinal
1
CNS
1
Conditions
Endometrial Neoplasms
15
Ovarian Neoplasms
5
Uterine Cervical Neoplasms
4
Carcinoma, Ovarian Epithelial
4
Breast Neoplasms
4
Endometrial Hyperplasia
3
Pancreatic Neoplasms
2
Neoplasms
2
Lung Neoplasms
2
Kidney Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Waldenstrom Macroglobulinemia
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sezary Syndrome
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pleural Effusion, Malignant
1
Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Interventions
pembrolizumab
42
Nivolumab
13
Carboplatin
11
Cyclophosphamide
10
olaparib
7
Paclitaxel
7
Ipilimumab
7
fludarabine
6
Gemcitabine
6
durvalumab
5
lenvatinib
4
cemiplimab
4
atezolizumab
4
Specimen Handling
4
Oxaliplatin
4
Magnetic Resonance Spectroscopy
4
Leucovorin
4
Fulvestrant
4
Fluorouracil
4
Cisplatin
4
Bevacizumab
4
veliparib
3
spartalizumab
3
sacituzumab govitecan
3
liposomal doxorubicin
3
avelumab
3
aldesleukin
3
Taxes
3
Interleukin-2
3
Doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Metformin
×
Gynecologic
×
Clear all
NCT02201381
2022-07-18
METRICS
Health Clinics Limited
Phase 3
Withdrawn